Pluristem Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 3, 2009, by Pluristem Therapeutics Inc., a Nevada corporation headquartered in Haifa, Israel. The report discloses a material definitive agreement entered into on January 29, 2009.
Key Financial Metrics and Transaction Details
The filing details a private placement of equity securities rather than standard operating financial results. Key transaction metrics include:
- Units Sold: 1,034,000 units (each consisting of one share of Common Stock and one warrant).
- Purchase Price: $1.16 per unit.
- Aggregate Proceeds: Approximately $1,200,000.
- Warrant Terms: Exercisable 181 days after issuance for a five-year period at an exercise price of $1.90 per share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels as this is a transaction-specific report.
Material Changes
The primary material change is the increase in outstanding equity and potential future equity through the issuance of 1,034,000 shares and corresponding warrants. The sale was conducted pursuant to an exemption from registration under Regulation D of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors beyond the standard disclosure that the warrant description is qualified by reference to the attached Exhibit 4.1. No unusual items or contingencies were disclosed in the text provided.
Investor Verification Checklist
- Verify the exact number of shares issued and the dilution impact on existing shareholders.
- Confirm the identity of the "certain investors" participating in the private placement.
- Review Exhibit 4.1 for the full legal terms and conditions of the warrants.
- Check subsequent filings for the actual cash proceeds received versus the approximate $1,200,000 stated.